Calliditas announces an additional seven year orphan drug exclusivity period for TARPEYO®

"We are delighted to have seven years of market exclusivity expiring in December 2030 for TARPEYO in the US, reflecting the new indication based on the long-term data generated," said CEO Renée Aguiar-Lucander. "We are delighted to have seven years of market exclusivity expiring inDecember 2030for TARPEYO in the US, reflecting the new indication based on the long-term data generated," said CEO Renée Aguiar-Lucander. CONTACT: For further information, please contact : Åsa...

"We are delighted to have seven years of market exclusivity expiring in December 2030 for TARPEYO in the US, reflecting the new indication based on the long-term data generated," said CEO Renée Aguiar-Lucander.

CONTACT:

For further information, please contact:

Åsa Hillsten, Head of IR & Sustainability, Calliditas

Tel.: +46 76 403 35 43, Email: asa.hillsten@calliditas.com

The information in the press release is information that Calliditas is obliged to make public pursuant to the EU Market Abuse Regulation. The information was sent for publication, through the agency of the contact persons set out above, on March 6, 2024 at 08:15 a.m. CET.

The following files are available for download:

 

 

View original content:https://www.prnewswire.co.uk/news-releases/calliditas-announces-an-additional-seven-year-orphan-drug-exclusivity-period-for-tarpeyo-302081089.html